Claims from The Gambia regarding possibly lethal Indian-made cough syrups prompted India’s Central Drugs Standard Control Organization (CDSCO), the country’s drug regulator, to conduct statewide risk-based inspections in 2022 and 2023. As a result of the inadequate manufacturing standards identified in numerous plants, the CDSCO has ordered 76 out of 237 pharmaceutical companies to halt production. Following the WHO and Gambia’s claims, the United States, Indonesia, Uzbekistan, the Marshall Islands, Micronesia, and the Gambia all expressed concerns about the quality of Indian drugs… Click Here to Read Full
